AstraZeneca's Etcamah Misses Primary Endpoint in SERENA-4 Phase III Trial
AZN is trading near its 52-week low of $146.1 (11% above the low).
Summary
AstraZeneca's SERENA-4 Phase III trial of Etcamah plus palbociclib missed its primary PFS endpoint in 1st-line ER-positive advanced breast cancer, limiting the drug's expansion beyond its current ESR1-mutation approval.
Key Events · Product Development and Regulatory · AZN
-
SERENA-4 Primary Endpoint Miss
The Phase III SERENA-4 trial of Etcamah plus palbociclib did not meet its primary endpoint of statistically significant progression-free survival improvement versus anastrozole plus palbociclib in upfront 1st-line ER-positive, HER2-negative advanced breast cancer.
-
Numerical Improvement Only
A numerical improvement in PFS was observed, but without statistical significance the data will not support a label expansion into the broader 1st-line population.
-
Etcamah Label Remains ESR1-Mutation Only
Etcamah remains approved only for patients with emergent ESR1 mutations based on SERENA-6; AstraZeneca is now emphasizing the importance of ESR1 testing for patients on first-line therapy.
-
Safety Profile Consistent
The safety profile of Etcamah plus palbociclib was consistent with the known safety profile of each medicine, with no new safety concerns identified.
Analysis · AZN · Life Sciences
The SERENA-4 trial of Etcamah plus palbociclib failed to meet its primary endpoint of statistically significant progression-free survival improvement in the upfront 1st-line setting for ER-positive, HER2-negative advanced breast cancer. This is a meaningful setback for AstraZeneca's ambition to expand Etcamah beyond its current ESR1-mutation niche into the broader 1st-line population. The company noted a numerical improvement in PFS, but without statistical significance the data will not support a label expansion. Etcamah remains approved only for patients with emergent ESR1 mutations based on SERENA-6, and AstraZeneca is now emphasizing the importance of ESR1 testing. The company is pivoting to the early breast cancer setting, where the CAMBRIA-1 and CAMBRIA-2 adjuvant trials (approximately 10,000 patients) represent the next major readouts. For a drug that was positioned as the only oral SERD with 1st-line benefit, this miss narrows the commercial opportunity and raises the stakes for the adjuvant program.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1156 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $162.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $248.4B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.